Shattuck Labs (NASDAQ:STTK) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Shattuck Labs (NASDAQ:STTK) posted its earnings results on Thursday. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.01, Zacks reports. Shattuck Labs had a negative net margin of 1,156.46% and a negative return on equity of 61.92%.

Shattuck Labs Price Performance

STTK stock traded down $0.04 on Thursday, reaching $1.14. 143,597 shares of the company were exchanged, compared to its average volume of 377,103. The firm has a market capitalization of $54.42 million, a PE ratio of -0.75 and a beta of 1.66. Shattuck Labs has a 12 month low of $0.94 and a 12 month high of $11.76. The stock’s fifty day moving average price is $1.24 and its 200 day moving average price is $1.51.

Analyst Ratings Changes

STTK has been the topic of a number of analyst reports. Leerink Partnrs raised Shattuck Labs to a “strong-buy” rating in a report on Monday, March 17th. HC Wainwright reiterated a “neutral” rating on shares of Shattuck Labs in a report on Thursday. Leerink Partners assumed coverage on shares of Shattuck Labs in a research report on Monday, March 17th. They issued an “outperform” rating and a $4.00 price target on the stock. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Shattuck Labs in a report on Thursday. Four equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $7.50.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.